Merck, Inc.
🇵🇭Philippines
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 167
- Registration Number
- NCT00736333
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Completed
- Conditions
- Chronic Hepatitis CHepatitis CHIV Infections
- Interventions
- Biological: PEG-IFN alfa-2bDrug: RBV
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 232
- Registration Number
- NCT00736242
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungBreast Neoplasms
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 97
- Registration Number
- NCT00732810
A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: Infliximab + methotrexate (MTX)
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 92
- Registration Number
- NCT00732875
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
Phase 3
Suspended
- Conditions
- HPV Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2011-01-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00733122
Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Peginterferon
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 244
- Registration Number
- NCT00732641
A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 87
- Registration Number
- NCT00730379
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 35
- Registration Number
- NCT00730275
Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)
Phase 1
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: IDX184Drug: Placebo
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00730431
Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00730912
© Copyright 2025. All Rights Reserved by MedPath